Volume: 9 Issue: 3
Year: 2021, Page: 58-63, Doi: https://doi.org/10.47799/pimr.0903.14
Received: March 23, 2021 Accepted: May 26, 2021 Published: May 26, 2021
Background: The comparative diagnostic accuracy of mean and lowest Ct values needs to be evaluated for the assessment of mycobacterial burden in tubercular cases. Mutation in any codon of 81 base-pair core regions prevents the hybridization of one or more of five overlapping Probes A-Ein Xpert MTB/RIF assay indicated by “missing probe. Molecular epidemiology of missing probes may prove useful in tracing the source of infection and selection of a more suitable drug regimen for treatment.
Methods: This study included 65 rifampicin resistant cases and an equal number of rifampicin sensitive cases detected by Xpert MTB/RIF assay. Only samples tested positive for tubercular bacilli were included. The information regarding the tubercular load, Ct values of five probes targeting the rpoB gene, lowest Ct value among the five probes, missing probe in rifampicin resistant cases and time taken for the entire cycle were recorded in each case.
Results: Lowest Ct is a stronger indicator of tubercular load than the mean Ct value. E probe was found to be missing in majority (64.6%) of the cases, followed by A (6.2%), B and D (4.6%), C (1.5%) probes. In 7.6% cases, more than one probe was missing. None of the probe was missing in 10.6% of rifampicin resistant cases.
Conclusions: Lowest Ct value was found to be a better tool than mean Ct value for the determination of mycobacterium burden. Molecular epidemiology of missing probes could be useful in the development of new probes for the detection of rifampicin resistance.
Keywords: CBNAAT, Xpert MTB/RIF, Tuberculosis, Cycle Threshold, Missing Probe, Rifampicin Resistance
2019. World Health Organization. Global tuberculosis report. https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1 Accessed on 15/06/2020
2018. World Health Organization. Global tuberculosis report. https://www.who.int/tb/publications/global_report/tb18_ExecSum_web_4Oct18.pdf?ua=1 Accessed on 15/06/2020
World Health Organization 2013. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children: policy update. World Health Organization. https://pubmed.ncbi.nlm.nih.gov/25473701/ Accessed on 27/06/2020
Lange, B, Khan, P, Kalmambetova, G, Al-Darrajih, A, Alland, D & Antonenka, U . 2017. Diagnostic Accuracy of the Xpert ® MTB/RIF Cycle Threshold Level to Predict Smear Positivity: A Meta-Analysis. Int J Tuberc Lung Dis 21(5):493–502.
Theron, G, Peter, J, Zyl-Smit, R van, Mishra, H, Streicher, E & Murray, S . 2011. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis. Am J RespirCrit Care Med 184:132–40.
Theron, G, Peter, J, Calligaro, G, Meldau, R, Hanrahan, C & Khalfey, H . 2014. Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartments. Sci Rep 4:5658.
Blakemore, R, Story, E, Helb, D, Kop, J, Banada, P & Owens, M R . 2010. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J ClinMicrobiol 48(7):2495–2501.
Perrin, F M, Woodward, N, Phillips, P P, McHugh, T D, Nunn, A J & Lipman, M C . 2010. Radiological cavitation, sputum mycobacterial load and treatment response in pulmonary tuberculosis. Int J Tuberc Lung Dis 14:1596–1602.
Palaci, M, Dietze, R, Hadad, D J, Ribeiro, F K, Peres, R L & Vinhas, S A . 2007. Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J Clin Microbiol 45:4064–6.
Rufai, S B, Kumar, P, Singh, A, Prajapati, S, Balooni, V & Singh, S . 2014. Comparison of Xpert MTB/RIF with line probe assay for detection of rifampin monoresistant Mycobacterium tuberculosis. J ClinMicrobiol 52:1846–1852.
Kanade, S, Nataraj, G, Mehta, P & Shah, D . 2019. Pattern of missing probes in rifampicin resistant TB by Xpert MTB/RIF assay at a tertiary care centre in Mumbai. Indian J Tuberc 66(1):139–143.
Sirgel, F A, Warren, R M, Böttger, E C, Klopper, M, Victor, T C & Helden, PD Van . 2013. The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks. PLoS One 8(3):e59414.
Ministry of Health & Family Welfare 2013. Guidance document for use of Catridge Based-Nucleic Acid Amplification Test (CB-NAAT) under Revised National TB Control Programme (RNTCP) issued central TB division, directorate general of health services. .
Xpert, Mtb/Rif Training Cepheid E & Manual, , Cepheid e Xpert MTB/RIF Training Manual. 2020. https://www.cepheid.com/Package%20Insert%20Files/Xpert-MTB-RIF-ENGLISH-Package-Insert-301-1404-Rev-F.pdf Accessed on 29.06.2020
Helb, D, Jones, M, Story, E, Boehme, C, Wallace, E & Ho, K . 2010. Rapid detection of mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J ClinMicrobiol 48(1):229–237.
Blakemore, R, Nabeta, P, Davidow, A L, Vadwai, V, Tahirli, R & Munsamy, V . 2011. A multisite assessment of the quantitative capabilities of the Xpert MTB/ RIF assay. Am J RespirCrit Care Med 184:1076–1084.
Lawn, S D & Nicol, M P . 2011. Xpert ® MTB/RIF Assay: development, evaluation implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol 6(9):1067–1082.
Fradejas, I, Ontañón, B, Muñoz-Gallego, I, Ramírez-Vela, M J & Lopez-Roa, P . 2018. The Value of Xpert MTB/RIF-generated CT values for predicting the smear status of patients with pulmonary tuberculosis. J ClinTuberc Other Mycobact Dis (13) 9–12.
Najjingo, I, Muttamba, W, Kirenga, B J, Nalunjogi, J, Bakesiima, R & Olwenyf, . 2019. Comparison of GeneXpert cycle threshold values with smear microscopy and culture as a measure of mycobacterial burden in five regional referral hospitals of Uganda- A cross-sectional study. PLoS One 14(5):e0216901. PMID: 31091275; PMCID: PMC6519814.
Najjingo, I, Muttamba, W, Kirenga, B J, Nalunjogi, J, Bakesiima, R & Olweny, F . 2019. Comparison of GeneXpert cycle threshold values with smear microscopy and culture as a measure of mycobacterial burden in five regional referral hospitals of Uganda- A cross-sectional study. PLoS ONE 14(5):e0216901.
Ulla, I, Shah, A A, Basit, A, Mazhar, A, Khan, A & Ullah, U . 2016. Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert MTB/RIF in Khyber Pakhtunkhwa, Pakistan: a retrospective study. BMC Infect Dis 16:413.
Mboowa, G, Namaganda, C & Ssengooba, W . 2014. Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert MTB/RIF in Kampala, Uganda: a retrospective study. BMC Infect Dis 14(1):481.
Raghuprakash R, Gerardo A-U 2017. Molecular epidemiology of rifampicin resistance in Mycobacterium tuberculosis using the GeneXpert MTB/RIF assay from a rural setting in India. J Pathogens 5.
Kaur, R, Jindal, N, Arora, S & Kataria, S . 2016. Epidemiology of rifampicin resistant tuberculosis and common mutations in rpoB gene of Mycobacterium tuberculosis: a retrospective study from six districts of Punjab (India) using Xpert MTB/RIF assay. J Lab Phys 8(2):96–100.
Gupta, A, Nagaraja, M R, Kumari, P, Singh, G, Raman, R & Singh, S K . 2014. Association of MDR-TB isolates with clinical characteristics of patients from Northern region of India. Indian J Med Microbiol 32:270–276.
Ochang, E A, Udoh, U A, Emanghe, U E, Tiku, G O, Offor, J B & Odo, M . 2016. Evaluation of rifampicin resistance and 81-bp rifampicin resistant determinant region of rpoB gene mutations of Mycobacterium tuberculosis detected with XpertMTB/Rif in Cross River State. Int J Mycobacteriol 5(1):145–146.
Goyal N, kashyap B, Puneeta H, NP S, Khanna A. Comparative Diagnostic Accuracy of Mean and Lowest Cycle Threshold Levels in Xpert MTB/RIF Assay and Molecular Epidemiology of Missing Probes In Rifampicin Resistant Tubercular Cases From A Tertiary Care Hospital. Perspectives in Medical Research. 2021;9(3):58-63 DOI: 10.47799/pimr.0903.14